Considering its potential effects on inflammatory macrophages and HSCs, STAT3 pathway is also a promising therapeutic target that can be explored in non‐alcoholic fatty liver disease (NAFLD), one of the most common liver‐related complications worldwide. The gene discussed is STAT3; the disease is metabolic dysfunction-associated steatotic liver disease.